Oppenheimer Reiterates $440.00 Price Target for Regeneron Pharmaceuticals (REGN)

Oppenheimer set a $440.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report released on Sunday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on REGN. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a sell rating to a hold rating in a report on Friday, November 23rd. TheStreet downgraded shares of Regeneron Pharmaceuticals from a b- rating to a c+ rating in a report on Tuesday, November 13th. Argus reiterated a buy rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 13th. Cowen reiterated a hold rating and issued a $385.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, August 16th. Finally, JPMorgan Chase & Co. set a $405.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a hold rating in a report on Wednesday, November 7th. Two research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and five have given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $408.42.

NASDAQ REGN opened at $372.80 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04. Regeneron Pharmaceuticals has a 12-month low of $281.89 and a 12-month high of $416.49. The company has a market capitalization of $39.57 billion, a PE ratio of 27.80, a price-to-earnings-growth ratio of 1.57 and a beta of 1.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The company had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same period last year, the company earned $3.99 earnings per share. The firm’s revenue was up 10.8% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post 19.48 EPS for the current fiscal year.

In related news, Director Joseph L. Goldstein sold 2,000 shares of the business’s stock in a transaction on Monday, September 24th. The shares were sold at an average price of $388.65, for a total transaction of $777,300.00. Following the transaction, the director now directly owns 13,000 shares in the company, valued at $5,052,450. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Sanofi sold 104,552 shares of the business’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total transaction of $42,519,207.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 108,552 shares of company stock worth $44,081,027. 12.42% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Capital World Investors boosted its position in Regeneron Pharmaceuticals by 5.3% during the third quarter. Capital World Investors now owns 6,384,323 shares of the biopharmaceutical company’s stock worth $2,579,522,000 after purchasing an additional 322,051 shares during the period. Vanguard Group Inc. boosted its position in Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc. now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after purchasing an additional 75,868 shares during the period. FMR LLC boosted its position in Regeneron Pharmaceuticals by 17.0% during the third quarter. FMR LLC now owns 5,016,501 shares of the biopharmaceutical company’s stock worth $2,026,867,000 after purchasing an additional 728,104 shares during the period. Loomis Sayles & Co. L P boosted its position in Regeneron Pharmaceuticals by 1.2% during the third quarter. Loomis Sayles & Co. L P now owns 3,346,280 shares of the biopharmaceutical company’s stock worth $1,352,031,000 after purchasing an additional 41,138 shares during the period. Finally, Janus Henderson Group PLC boosted its position in Regeneron Pharmaceuticals by 12.7% during the second quarter. Janus Henderson Group PLC now owns 1,802,740 shares of the biopharmaceutical company’s stock worth $621,927,000 after purchasing an additional 203,306 shares during the period. 67.24% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: Understanding each part of a balance sheet

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit